Comparison of Visual Outcomes, Wavefront Analysis, Contrast Sensitivity and Glare Testing Following Cataract Extraction Between Acrysof Single-Piece IOL and Acrysof WF

Medical University of South Carolina0 个研究点目标入组 30 人2004年7月

适应症Cataract Extraction

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Cataract Extraction
发起方: Medical University of South Carolina
入组人数: 30
主要终点: Contrast sensitivity
状态: 已完成
最后更新: 19年前

概览研究者入排标准结局指标相似试验

概览

简要总结

To determine quality of vision post cataract extraction and intraocular lens (IOL) implantation of 2 different acrylic intraocular lenses: Acrysof® Single-Piece IOL and Acrysof® WF, through evaluation of contrast sensitivity, glare testing, visual outcomes, wavefront, corneal topography, and patient satisfaction.

注册库

clinicaltrials.gov

开始日期

2004年7月

结束日期

2005年5月

最后更新

19年前

研究类型

Interventional

研究设计

Parallel

性别

All

研究者

发起方

Medical University of South Carolina

入排标准

入选标准

•Unilateral or bilateral cataract
•Eligible for phacoemulsification with primary implantation of a posterior chamber IOL. If bilateral, patient will receive the same IOL than the fellow eye.
•Expected maximum of 4 weeks and minimum of 1 week interval between primary and second eye surgeries when bilateral.
•Best corrected visual acuity (BCVA) should be no better than 20/40 in the presence of a glare source using Snellen visual acuity. In the Snellen visual acuity chart, better than 20/40 will be at least 3 letters read correctly in the 20/30 line.
•Naturally dilated pupil (in dim light) ≥ 4.0 mm in both eyes.

排除标准

•Preoperative ocular pathology potentially affecting visual acuity
•Previous intraocular or corneal surgery.
•Keratometric astigmatism exceeding 1.5 diopters.
•Planned postoperative refraction for mono-vision.
•Current contact lens usage.
•Other ocular surgery at the time of the cataract extraction.
•Uncontrolled diabetes.
•Any neurological condition that might interfere with performance of required test.
•Auto-immune deficiency disease.
•Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or study device implantation or may interfere with the interpretation of study results.